Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Eaton Corporation plc (ETN) vs Cassava Sciences Inc (FLNA) Price & Performance

Eaton Corporation plcTrade
Cassava Sciences IncTrade

Price performance (Past 24H)

Key statistics

Eaton Corporation plc vs Cassava Sciences Inc — how do they compare? Eaton Corporation plc trades at $470 (market cap $172.82B), while Cassava Sciences Inc trades at $0.97 (market cap $47.75M). The key difference: Eaton Corporation plc is far larger — about 3619.3× Cassava Sciences Inc's market cap, and Eaton Corporation plc pays a 0.99% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.

ETNFLNA
Market Cap
$172.82B$47.75M
Sector
TechnologyHealth
52-Week High
$459.29$4.64
52-Week Low
$315.82$0.87
Enterprise Value
$193.45B-$34.93M
Dividend Yield
0.99%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Eaton Corporation plc

No Aura AI signal available yet.

Cassava Sciences Inc

FLNA trades at $0.9973, up 0.23% with a bearish technical signal despite recent earnings beats. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though cash burn improved from -$33M to -$30M projected for 2026. Analyst consensus is strongly bullish with 8 buy ratings versus 4 hold ratings.

The outlook remains challenging due to persistent losses and negative cash flow, but analyst optimism and continued progress in TSC-related epilepsy therapies provide potential catalysts. Key risks include execution challenges in clinical development and the company's ability to secure additional funding.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Eaton Corporation plc

Eaton is a global power management company providing energy-efficient solutions for electrical, aerospace, and industrial sectors. It focuses on improving sustainability through intelligent power technology.

Read more on ETN

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA